Revive Therapeutics Ltd
Change company Symbol lookup
Select an option...
RVVTF Revive Therapeutics Ltd
LDNXF London Stock Exchange Group PLC
JOE St. Joe Co
OMC Omnicom Group Inc
CHDN Churchill Downs Inc
SGTB Kuboo Inc
BBBMX BBH Limited Duration Fund Class N
VICI VICI Properties Inc
DDS Dillard's Inc
ALIN-E Altera Infrastructure LP
Go

Health Care : Pharmaceuticals | Small Cap Growth
Based in Canada
Company profile

Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.

Closing Price
$0.3913
Day's Change
-0.0059 (-1.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.4081
Day's Low
0.3848
Volume
(Light)
Volume:
564,474

10-day average volume:
1,191,574
564,474

Display:

Providers:

UpdateCancel
All providers
May 03, 2021
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that...(Globe Newswire)

April 27, 2021
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an...(Globe Newswire)

April 22, 2021
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the successful...(Globe Newswire)

April 15, 2021
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to announce that, further to its...(Globe Newswire)

PharmaTher Provides Update on Psychedelic Product Programs

PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial...(Globe Newswire)

April 14, 2021
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

The psychedelics industry may appear to have suddenly emerged as one of the hottest corners of the stock market, but researchers have been working for decades to show the efficacy of these treatments and regulators are just starting to appreciate...(PR Newswire)

April 12, 2021
Revive Adjourns Annual and Special Meeting

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces that its Annual and Special Meeting (the...(Globe Newswire)

April 08, 2021
Revive Provides Dial-In Information for Annual and Special Meeting

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in...(Globe Newswire)

March 24, 2021
Proactive news headlines including Clean Seed Capital Group, Plurilock Security, Dalrada Financial and Revive Therapeutics

EQNX::TICKER_START EQNX::TICKER_END About Proactive With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world's major stock exchanges...(Globe Newswire)

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the...(Globe Newswire)

March 19, 2021
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of...(Globe Newswire)

March 17, 2021
Why Canada is Becoming a Hub for Psychedelics Research and Development

Canada has become home to some of the most important research and development happening today in the mental health and wellness space. Psychedelic therapy emerged as a breakthrough mental health treatment, and Canadian companies are leading the way...(PR Newswire)

March 09, 2021
With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market

The time of "Tune In... Turn On... and Dropout" psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds... they were universally declared taboo. My, but how...(PR Newswire)

March 02, 2021
Global Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026

Many people and investors may be confused, thinking that the Psychedelics market is part of the cannabis market. It is not a way to get higher 'highs' in the legal cannabis market... it will make its mark in medicine. Various articles and reports...(PR Newswire)

February 26, 2021
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the...(Globe Newswire)

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the...(Globe Newswire)

February 23, 2021
A Magical Era of Body/Mind Health and Wellness with Functional and Psychedelic Mushrooms

Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - February 23, 2021) -  Investorideas.com, a leading investor news resource on health and wellness stocks releases a sector snapshot looking at a health revolution taking place...(Newsfile)

February 17, 2021
Revive Therapeutics Acquires Unique Psilocybin Assets

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its...(Globe Newswire)

February 12, 2021
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed...(Globe Newswire)

February 11, 2021
Psychedelics are Gaining Traction as Therapies and Medicines

The psychedelic drug market continues to follow a similar path to the cannabis segment. It is now slowly getting more attention from investors as the stigma surrounding psychedelic drugs fades. In particular, the growing acceptance of using...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.